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Abstract
Signaling via the type 4-melanocortin receptor (MC4R) is an important determinant of body weight in mice and humans,
where loss of function mutations lead to significant obesity. Humans with mutations in the MC4R experience an increase in
lean mass. However, the simultaneous accrual of fat mass in such individuals may contribute to this effect via mechanical
loading. We therefore examined the relationship of fat mass and lean mass in mice lacking the type-4 melanocortin receptor
(MC4RKO). We demonstrate that MC4RKO mice display increased lean body mass. Further, this is not dependent on changes
in adipose mass, as MC4RKO mice possess more lean body mass than diet-induced obese (DIO) wild type mice with
equivalent fat mass. To examine potential sources of the increased lean mass in MC4RKO mice, bone mass and strength
were examined in MC4RKO mice. Both parameters increase with age in MC4RKO mice, which likely contributes to increases
in lean body mass. We functionally characterized the increased lean mass in MC4RKO mice by examining their capacity for
treadmill running. MC4R deficiency results in a decrease in exercise performance. No changes in the ratio of oxidative to
glycolytic fibers were seen, however MC4RKO mice demonstrate a significantly reduced heart rate, which may underlie their
impaired exercise performance. The reduced exercise capacity we report in the MC4RKO mouse has potential clinical
ramifications, as efforts to control body weight in humans with melanocortin deficiency may be ineffective due to poor
tolerance for physical activity.
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Introduction
The type 4-melanocortin receptor (MC4R) is a known
regulator of somatic growth. Genetic blockade [1] or loss of
function of the MC4R results in increased linear growth in
rodents [2] and humans [3]. Interestingly, humans with MC4R
deficiency have a lower body fat content, and therefore higher
lean mass when compared to leptin-deficient individuals with
similar body mass index (BMI). MC4RKO mice resist lean mass
loss due to tumor growth [4] and chronic renal failure [5].
Furthermore, pharmacologic blockade of the MC4R attenuates
lean mass loss in a multitude of catabolic conditions [4–8].
Despite this association, a thorough characterization of the
relationship between melanocortin signaling and lean mass has
not been performed.
Increased bone mineral density has also been reported in
humans [3] and animals [9] with MC4R deficiency, suggesting
that increases in bone mass may account for some of the lean
mass phenotype seen in these situations. Complicating the
interpretation of increased lean mass in melanocortin deficiency
is the compensatory muscle hypertrophy and bone mineralization
that occur in parallel with increasing fat mass. As body weight
increases, muscle and bone mass increase, presumably in
response to increased mechanical loading. Therefore, we
examined the body composition of MC4RKO and diet-induced
obese (DIO) mice to investigate the role of melanocortin signaling
in regulating the accrual of lean mass independent from increases
in fat mass.
Our results show that young MC4RKO mice initially have an
increase in fat mass without changes in lean mass relative to WT
mice. However, increased lean mass rapidly develops relative to
DIO-WT mice, which display an equivalent rate of fat mass
accrual. This increased lean mass is associated with a decreased
exercise performance independent of increased body weight and
with increased grip strength. Additionally, MC4RKO mice have a
late onset increase in bone mass and strength. Collectively, these
results demonstrate that melanocortin signaling is a fundamental
determinant of lean body mass, a component of which includes
bone mass.
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MC4R Deficiency Increases the Accrual of Lean Mass
Independent from Changes in Fat Mass
To examine the time course of the increased lean mass
phenotype in MC4RKO mice, we examined young WT and
KO mice at 7 weeks of age. At this time point, MC4RKO mice
were not yet significantly heavier than WT mice (21.760.5 g for
KO vs. 21.260.3 g for WT, p=0.09) (Figure 1 A). Interestingly,
fat mass was increased in MC4RKO relative to WT mice
(2.260.1 g for KO vs. 1.760.1 g for WT), with no differences
evident in lean mass (18.860.4 g for KO vs. 18.460.2 g for WT)
(Figure 1 B, C). This resulted in an increased fat mass percentage
and a decreased lean body mass percentage in KO mice relative to
WT mice (Figure 1 D, E).
We next explored whether an increased lean mass phenotype
would occur with aging in the MC4RKO mice. To control for the
effects of increasing body weight and fat mass, we placed a subset
of WT control mice on a high fat diet (HFD) for 4 weeks to
generate DIO, while the remainder of the WT animals were
maintained on low-fat chow (Chow-WT). Despite DIO-WT mice
gaining significant weight over the month of high fat feeding
relative to Chow-WT mice, chow-fed MC4RKO mice gained
more weight and were significantly heavier at 12 weeks of age
(34.960.9 g for KO vs. 31.560.4 g for DIO-WT vs. 25.660.4 for
Chow-WT) (Figure 1 F). HFD produced a significant increase in
fat mass in WT mice over the 4-week period relative to Chow-WT
mice. This increase paralleled the fat mass gain in chow-fed
MC4RKO mice (6.760.5 g for KO vs. 7.460.5 g for DIO-WT
vs. 0.560.1 g for Chow-WT) (Figure 1 G, I). As a result, at the end
of the 4-week period, WT-DIO and MC4RKO mice exhibited
equivalent fat mass (8.960.5 g for KO vs. 9.160.5 g for WT vs.
2.260.2 g for Chow-WT). Both WT-Chow and WT-DIO mice
gained equivalent fat mass over the course of 4 weeks, however,
MC4RKO mice gained nearly double the lean mass over the one-
month period (6.260.5 g for KO vs. 3.560.4 g for WT vs.
3.060.4 for Chow-WT) (Figure 1 H, J). This resulted in a
significantly increased lean mass (25.060.4 g for KO vs.
21.660.3 g for WT vs. 21.860.4 g for Chow-WT) in MC4RKO
mice relative to DIO-WT mice (Figure 1 H, K, L). When
controlling for body weight by only considering the 5 heaviest
DIO-WT mice and the 5 lightest MC4RKO mice the differences
in body composition become even more pronounced, with
MC4RKO mice displaying 25% less fat mass than weight-
matched DIO-WT mice.
MC4RKO Mice Exhibit Increased Grip Strength and
Decreased Exercise Performance
To examine the endurance capacity of MC4RKO mice, they
were subjected to treadmill running. Despite only mild differences
in body composition, MC4RKO mice showed a dramatic
reduction in treadmill running time, and distance covered
(Figure 2 A, B). MC4RKO mice ran for less than half the time
and covered only one third of the distance achieved by WT mice.
There was no significant correlation between body weight and
either run time or distance covered in WT or MC4RKO mice
(p=0.2 for WT and p=0.3 for MC4RKO). The endurance
performance of MC4RKO mice was examined again relative to
DIO-WT mice at 12 weeks of age, and again a significantly
reduced run time and total distance traveled was observed in
MC4RKO mice (Figure 2 C, D). BW was not a determining factor
in the running performance of MC4RKO mice as it showed no
significant correlation with run time or total distance covered for
either WT or MC4RKO mice (p=0.8 for WT, p=0.8 for
MC4RKO). To determine if a functional deficit in skeletal muscle
might be responsible for the poor exercise endurance phenotype of
MC4RKO mice, we measured grip strength and found that it was
slightly increased in MC4RKO mice relative to WT mice (Figure 2
E). These data suggest that melanocortin signaling plays a
fundamental role in determining skeletal muscle function.
MC4RKO Mice Have Normal Muscle Fiber Composition
and a Low Resting Heart Rate
To examine the possible causes for the reduced running
performance in the MC4RKO mouse, we examined heart rate in
MC4RKO mice. We found a significant reduction in heart rate in
MC4RKO mice relative to WT controls, suggesting that impaired
cardiac performance underlies the endurance deficit in these
animals (Figure 3 A). To further explore this finding, we examined
the expression of b1 and b2 adrenergic receptors in cardiac muscle
(Figure 3 B). While the expression of the b2 adrenergic receptor
was unchanged in MC4RKO mice, the b1 receptor was decreased
in expression. We additionally examined the expression of b1
adrenergic receptor kinase (Adrbk1), which regulates b1 receptor
signaling. No differences in Adrbk1 expression were observed
between genotypes. Finally, expression of the type 2 muscarinic
cholinergic receptor (Chrm2) was also examined, which underlies
parasympathetic suppression of heart rate. While a trend toward
decreased expression was seen in MC4RKO mice, this did not
reach the level of statistical significance (p=0.052). The decreased
expression of the b1 adrenergic receptor is of particular interest, as
decreased signaling via this receptor could potentially explain the
decreased heart rate seen in MC4RKO mice. We also examined
the fiber composition of the gastrocnemius and soleus muscles, as
alterations in the relative abundance of glycolytic versus oxidative
fibers could potentially explain the poor exercise endurance
phenotype in the MC4RKO mouse. The rodent gastrocnemius is
composed of predominantly type IIb glycolytic fibers, with
scattered centrally located type IIa intermediate fibers [10]. In
contrast the mouse soleus is made up of predominantly type IIa
fibers at approximately a 2:1 ratio with type I oxidative fibers. We
saw no differences in the numbers of type IIa immunoreactive
fibers in the gastrocnemius or soleus, and also saw no differences in
the number of type I immunoreactive fibers in the soleus between
genotypes (Figure 3 B–J). This suggests that alterations in fiber
composition are not responsible for the reduced exercise
performance in MC4RKO mice.
Aged MC4RKO mice have increased bone mass and
strength
Bone mass is known to be elevated in MC4RKO mice and
skeletal mass is a major contributor to whole body lean mass.
Therefore, we examined the skeletal phenotype in middle aged (20
weeks) and old (40 weeks) MC4RKO mice. Despite the significant
discrepancy in overall body size between the MC4RKO and WT
mice, there were no observed differences in femoral length at
either 20 or 40 weeks of age (Tables 1 and 2). In 20-week-old
MC4RKO mice, whole body and femoral bone mineral density
(BMD) were significantly increased (by 6% and 11%, respectively)
as compared to WT mice. By 10 months of age the markedly
increased body size of the MC4RKO mice precluded assessment
by the pixiMusH densitometer, but femoral and L5 vertebral BMD
were significantly increased (by 11% and 13%, respectively) as
compared to WT mice.
Although trends existed in bone strength and geometry, there
were no statistical differences in femoral geometry or strength at
20 weeks of age (Table 1). However, by 40 weeks of age
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greater cortical thickness and 45% greater moment of inertia than
WT mice (Table 2). These differences in femoral geometry were
accompanied by a 29% increase in ultimate failure load and 21%
increase in stiffness (Table 2). In addition to the femoral
morphological differences, the vertebral BV/TV and trabecular
number of 10-month-old MC4RKO L5 vertebrae compared to
WT were 13% and 28% greater, respectively. Consistent with the
increased vertebral bone volume and trabecular number,
MC4RKO mice exhibited a 57% increase in trabecular connec-
tivity density compared to WT mice. Representative two-
dimensional frontal planar mCT images illustrating the differences
Figure 1. MC4RKO Mice Rapidly Accrue Lean Mass Independent from Fat Mass. (A) Body weights of 7-week-old male MC4RKO mice
(n=20) were compared with age and weight matched WT mice (n=10). (B) MC4RKO mice have increased fat mass, (C) but normal lean mass. (D) Fat
mass as a percentage of body weight (BW) is increased in MC4RKO mice. (E) Lean mass as a percentage of body weight is unaltered in MC4RKO mice.
A subset of WT mice (n=13) were placed on HFD (DIO-WT) for 4 weeks, from 8–12 weeks of age, while the remainder (n=7) were maintained on a
low fat control diet (Chow-WT). MC4RKO mice were maintained on a low fat control diet during this time. (F) MC4RKO mice weighed more at 12
weeks of age than DIO-WT mice. (G) MC4RKO mice have equivalent fat mass at 12 weeks of age compared with DIO-WT mice. (H) MC4RKO mice have
increased lean mass relative to DIO-WT mice at 12 weeks of age. (I) Mice fed a HFD for 4 weeks gain an equivalent amount of fat mass as MC4RKO
mice. (J) MC4RKO mice gain more lean mass than DIO-WT mice. (K) % body fat, (L) and % lean mass. Data represented as mean 6 s.e.m. **=P,0.01,
***=P,0.001 as calculated by unpaired t-test or one-way ANOVA with a Bonferroni post test.
doi:10.1371/journal.pone.0042183.g001
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and MC4RKO mice are presented in Figure 4. These data
demonstrate that MC4RKO mice have increased bone mass that
evolves in concert with the development of severe obesity.
Discussion
Increased lean mass has been associated with MC4R mutations
in humans [3,11] and melanocortin blockade protects against lean
mass loss in experimental cachexia in rodents [6,12,13]. Further-
more, MC4RKO mice exhibit increased body length, suggesting a
role for signaling at the MC4R in restraining somatic growth [2].
Obesity results in an increase in both fat and lean body mass,
although fat mass increases to a larger extent, increasing the fat:
lean ratio. While MC4RKO loss of function has been associated
with increased lean mass for a given BMI, a thorough
characterization of body composition has yet to be performed to
allow for the deconvolution of increasing adiposity from alterations
in lean mass [4,7,14,15]. Furthermore, while it has been suggested
that an increase in lean mass associated with MC4R blockade is
the result of increased muscle mass, the function of skeletal muscle
in this setting has not been examined. This work demonstrates that
MC4RKO mice accumulate lean mass at an accelerated rate
independent from the accumulation of fat mass. While MC4R
deficiency in humans is associated with increased lean mass
relative to leptin deficient individuals, we confirm the association
between MC4R loss-of-function and increased lean mass in
MC4RKO mice relative to DIO mice.
Multiple lines of evidence suggest that signaling via the MC4R
can influence metabolic pathways in peripheral tissues via the
autonomic nervous system [16,17]. The regulation of adipose
tissue by melanocortin signaling has been extensively character-
ized, where signaling at the MC4R stimulates lipolysis. However,
the contribution of melanocortin signaling to the regulation of lean
tissue mass has not been described. In addition to the potential
regulation of lean mass by the autonomic nervous system,
melanocortin signaling regulates the levels of numerous hormones.
Both insulin and circulating IGF-1 levels are elevated in humans
with MC4R mutations, which would be expected to exert
powerful trophic effects on muscle [18]. In total, these features
of MC4R deficiency would be expected to promote the accrual of
lean mass.
Bone mass represents another significant component of total
lean mass. Elevated bone mass was found in multiple cohorts of
MC4R deficient humans, and in MC4RKO mice [9]. Further-
more, MC4R deficient humans display isolated decreases in
circulating markers of bone resorption, without alterations in
markers of bone formation [9]. Consistent with these findings, we
found significant elevations in bone mineral density in 5-month
and 10-month-old MC4RKO mice. At both time points exam-
ined, significant elevations in body weight were already present in
MC4RKO mice. Some controversy exists as to whether obesity is
associated with increased bone mass [19]. Obese individuals
demonstrate increased bone mass. However, when the effects of
mechanical loading due to increased body weight are accounted
for, this association is no longer present. As the MC4RKO mice
used in our study were already obese when bone parameters were
measured, it is difficult to assess the role of decreased melanocortin
signaling in regulating bone mass independent from increases in
body weight. It has been suggested that the elevated bone mass in
MC4RKO mice arises from elevated cocaine and amphetamine
regulated transcript (CART) levels [9]. Indeed, mice lacking the
prohormone convertase carboxypeptidase E are obese with low
bone mass and are unable to produce mature a-melanocyte
stimulating hormone (the primary MC4R ligand) or CART [20].
Figure 2. The type 4-melanocortin receptor is a critical regulator of exercise performance. 8-week-old male MC4RKO mice (n=13) and
age and weight matched WT controls (n=10) were subjected to treadmill running at escalating speed. (A) MC4RKO mice showed decreased total
treadmill run time. (B) MC4RKO mice showed decreased treadmill run distance. No correlation between run time or run distance with body weight
was observed. WT mice (n=13) were placed on HFD (DIO-WT) for 4 weeks until 12 weeks of age. MC4RKO mice were maintained on a low fat control
diet. After this time, treadmill endurance was assessed. (C) MC4RKO showed a significantly attenuated run time (D) and run distance compared with
WT mice. There was no significant correlation between run time or run distance and body weight. (E) Grip strength was also measured prior to the
initiation of high fat feeding, and was increased in MC4RKO mice. Data represented as mean 6 s.e.m. *=P,0.05, **=P,0.01, ***=P,0.001 as
calculated by unpaired t-test.
doi:10.1371/journal.pone.0042183.g002
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in the regulation of bone mass. Additionally, there is some
evidence to suggest that melanocortin signaling has direct
influences on bone. The MC4R is expressed both on osteoblasts
and osteoclasts [21,22], demonstrating the potential for melano-
cortin peptides to directly influence bone metabolism. While
increased bone mass has been previously described in the
MC4RKO mouse, our study is the first to show that bone
strength is also increased by MC4R deficiency. Importantly, this
demonstrates that in addition to regulating bone mass, melano-
cortin signaling is also an important determinant of bone quality.
To further evaluate the function of skeletal muscle in
MC4RKO mice, we assessed treadmill run time as a measure of
endurance. MC4RKO mice were markedly deficient in their
exercise capacity. Furthermore, increased body weight does not
appear to be responsible for this effect, as there was no relationship
between body weight and treadmill run times. We also found that
grip strength is slightly increased in MC4RKO mice, suggesting a
shift in the balance of muscle fiber types. However, there were no
differences in fiber type distribution in MC4RKO mice, demon-
strating that an overt change in the balance of oxidative and
glycolytic fibers is not responsible for the exercise phenotype of
these animals. MC4RKO mice also have a dramatically decreased
resting heart rate, consistent with previous findings in MC4R
deficient mice and humans [23,24]. It is possible that an inability
to achieve peak exercise-induced cardiac output underlies the
exercise phenotype of the MC4RKO mouse. MC4RKO mice
have normal heart weights and gross appearance [8]. However,
the central melanocortin system is fundamental regulator of
autonomic outflow to many tissues, suggesting alterations in
cardiac sympathetic nerve activity underlie this phenomenon
[17,25]. Indeed, central administration of melanocortin agonists
produces a relative tachycardia [26]. However, there is likely some
ligand and neuroanaotomic specificity to this effect as others have
found that melanocortin agonists produce bradycardia [27].
Interestingly, we found decreased expression of the b1 adrenergic
Figure 3. Mice lacking the type 4 melanocortin receptor have a normal muscle fiber type distribution with a decreased resting
heart rate. Skeletal and cardiac muscle was examined in in 11-week old male WT (n=5) and MC4RKO (n=6) mice. (A) Resting heart rate was
decreased in MC4RKO mice. (B) Cardiac gene expression in male MC4RKO and aged matched control mice at 35 weeks of age (n=5–6/group). (C–E)
No differences were seen in type I fiber number in the soleus, (F–H) type IIa fibers in the soleus or (I–K) type IIa fibers in the gastrocnemius. Scale
bar=100 mm. *=P,0.05, ***=P,0.001 as calculated by unpaired t-test.
doi:10.1371/journal.pone.0042183.g003
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cardiac in addition to CNS changes may underlie decreased heart
rate in MC4RKO mice. While a complete mechanistic description
of this phenomenon is beyond the scope of this work, it is clear that
global deficiency of the MC4R results in a decrease in resting heart
rate. Interestingly, previous studies have only demonstrated
significant decreases in heart rate during the night cycle when
the animals are active, although a trend toward decreased heart
rate was observed during the day [23]. Technical considerations
resulting in decreased variability likely account for our ability to
detect a significant suppression of heart rate in MC4RKO mice
during the day (Measurement in anesthetized mice over a short
time period vs. average heart rate over 12 hours in freely moving
animals). However, the finding that MC4RKO mice fail to
appropriately increase their heart rate during a time of increased
activity (night cycle) is consistent with heart rate as a determinant
of exercise impairment in MC4RKO mice. Another plausible
explanation is that the central melanocortin system is also a
regulator of glucose uptake by skeletal muscle. Central adminis-
tration of melanocortin agonists increases the activity of AMP-
activated protein kinase (AMPK), which results in the transloca-
tion of the type 4 glucose transporter to the cell membrane [16].
Therefore, impaired glucose uptake in skeletal muscle consequent
to decreased AMPK activity also has the potential to underlie the
endurance defect in MC4RKO mice.
Signaling via the MC4R controls multiple facets of growth and
metabolism. While numerous studies have focused on the
regulation of fat mass by the central melanocortin system, the
regulation of lean mass has not been previously explored. We
demonstrate increased lean mass in the setting of MC4R
deficiency with an increased bone mass significantly contributing
to this finding. Furthermore, MC4R deficiency results in impaired
exercise performance. This result has important clinical ramifica-
tions for the care of patients with the melanocortin obesity
syndrome, where reduced ability to sustain physical activity may
confound attempts to control body weight via exercise.
Materials and Methods
Ethics Statement
Experiments were conducted in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals, and approved by the Animal Care and Use Committee
of Oregon Health & Science University, Protocol Number A931.
Animals
Wild type C57BL/6J mice (20–25 g) were obtained from The
Jackson Laboratory (Bar Harbor, ME). MC4RKO mice were used
as previously reported [2]. MC4RKO mice were backcrossed at
least 10 generations into the C57BL/6J strain. All animals were
maintained on a normal 12:12 hr light/dark cycle and provided ad
libitum access to water and food (Purina rodent diet 5001; Purina
Mills, St. Louis, MO). The high fat diet (HFD) (D12492, Research
Diets, Inc.) contains 60% fat (5.24 kcal/g). Mice were sacrificed by
Table 1. Skeletal Phenotype of WT and MC4RKO Mice at 20
Weeks.
Age=20 Weeks WT MC4RKO p value
Whole Body Weight (g) 22.260.3 31.561.5 ,0.0001
Length (cm) 9.5160.10 9.6860.09 NS
BMD (mg/cm
2)4 9 . 2 60.4 52.060.8 ,0.05
Femur Length (mm) 15.560.01 15.960.01 NS
BMD (mg/cm
2)4 8 . 7 60.5 54.161.0 ,0.0005
Ct. Ar. (mm
2) 0.6860.01 0.7260.03 NS
Ct. Th. (mm) 0.1660.003 0.1760.006 NS
Ixx (mm
4) 0.1060.004 0.1160.007 NS
Ult. Force (N) 15.460.6 17.661.2 NS
Stiffness (N/mm) 100.362.4 105.965.0 NS
The skeletal phenotype of twenty-week-old female WT (n=14) and MC4RKO
mice (n=9) was examined by DEXA and microtomography. Bone strength was
determined by 3 point bending to failure. Values are represented as mean 6
SEM. Statistical significance was assessed by Students t-test, with significant
differences assigned a p value,0.05.
doi:10.1371/journal.pone.0042183.t001
Table 2. Skeletal Phenotype of WT and MC4RKO Mice at 40
Weeks.
Age=40 weeks WT MC4RKO p value
Whole Body Weight (g) 24.560.4 61.462.1 ,0.0001
Length (cm) 9.4460.07 10.360.05 ,0.0001
Femur Length (mm) 16.160.05 16.260.05 NS
BMD (mg/cm
2) 51.760.8 57.660.6 ,0.0001
Ct. Ar. (mm
2) 0.7660.02 0.9160.02 ,0.0001
Ct. Th. (mm) 0.1860.004 0.2060.004 ,0.0001
Ixx (mm
4) 0.1260.004 0.1860.006 ,0.0001
Ult. Force (N) 19.560.6 25.060.8 ,0.0001
Stiffness (N/mm) 117.464.5 142.564.3 ,0.0001
L5 Vertebra BMD (mg/cm
2) 43.160.6 48.860.7 ,0.0001
BV/TV (%) 20.760.8 25.761.0 ,0.005
Tb No 3.460.1 4.460.1 ,0.0001
Tb Th 60.861.0 61.560.7 N.S.
Conn Dens 86671 3 5 67 ,0.0001
The skeletal phenotype of forty-week-old female WT (n=11) and MC4RKO mice
(n=12) was examined by DEXA and microtomography. Bone strength was
determined by 3 point bending to failure. Vertebral morphometric variables
describing bone microstructure were computed using direct 3D methods.
Values are represented as mean 6 SEM. Statistical significance was assessed by
Students t-test, with significant differences assigned a p value,0.05.
doi:10.1371/journal.pone.0042183.t002
Figure 4. Trabecular bone microarchitecture of WT and
MC4RKO mice at 40 Weeks. Two-dimensional frontal planar mCT
images of the fifth vertebral body were obtained as described in the
Methods sections.
doi:10.1371/journal.pone.0042183.g004
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Body composition
Mouse body composition analysis was performed using a 4-in-1
small animal MRI (Echo Medical Systems, Houston, TX).
Treadmill
Exercise performance was measured with an Exer-3/6 treadmill
(Columbus Instruments, Columbus, OH). Animals were condi-
tioned in the treadmill chamber every other day for one week prior
to the experiment. At the start of training sessions, animals were
acclimatized to the treadmill chamber for ten minutes with the
treadmill off. The speed of the treadmill was started at 6 m/min
was increased by 1 m/min every min. Once 10 m/min was
reached, the animals were run for 5 minutes. On the day of the
experiment, the treadmill was started at 6 m/min, and the speed
was increased by 1 m/min every 10 minutes until 15 m/min was
reached. Animals were run at 15 m/min until exhaustion.
Real Time PCR
Heart RNA was extracted using the RNeasy fibrous tissue mini
kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. cDNA was transcribed using Taqman reverse
transcription reagents and random hexamers according to the
manufacturers instructions. PCR reactions were run on an ABI
7300, using Taqman universal PCR master mix, using Taqman
gene expression assays: Adrb2 (Mm02524224_s1), Adrb1
(Mm00431701_s1) Chrm2 (Mm01701855_s1), Adrbk1
(Mm00804778_m1) (Applied Biosystems, Carlsbad, CA). Relative
expression was calculated using the delta-delta Ct method, and
was normalized to vehicle treated control. Statistical analysis was
performed on the normally distributed delta-Ct values.
Fiber type analysis
For analysis of muscle fiber type, 9 mm unfixed cryosections of
gastrocnemius were blocked for 1 hour in PBS/1% BSA/10%
goat serum, and then incubated overnight in primary antibody
diluted 1:250 in PBS/1% BSA/10% goat serum. The following
primary antibodies were used: SC-71 for myosin IIa, BF-F3 for
myosin IIb (Developmental Studies Hybridoma Bank, University
of Iowa, Iowa City, IA), and anti Myosin I (Vector Labs,
Burlingame, CA). Sections were washed in PBS/0.025% triton-X-
100, and incubated with a goat anti-mouse Alexafluor-488 nm
labeled secondary antibody (Invitrogen, Carlsbad, CA) diluted
1:500 in PBS/10% BSA. Sections were mounted with Vectashield
fluorescent mounting media (Vector Labs, Burlingame, CA).
Images were acquired on a Leica DM4000 B microscope, using a
Leica DFC340 FX camera at ambient temperature at 1006
magnification using Leica Applications Suite 3.6 software (Leica,
Buffalo Grove, IL).
Grip Strength
Grip strength was measured using a Grip Strength Meter
(Columbus Instruments, Columbus, OH). Five measurements
were collected per animal. The high and low value for each animal
were discarded, and the middle three values averaged.
Heart rate
Mouse heart rate was measured using a Vivo770 (Visualsonics,
Toronto, ON) under isoflurane anesthesia. Mice were maintained
under anesthesia for one hour prior to heart rate measurement to
establish a stable baseline.
Bone Phenotype
Female mice from the wild type (WT, C57BL/6) and
MCR4KO strains were bred under identical conditions. All
procedures were approved by the VA Institutional Animal Care
and Use Committee and performed in accordance with National
Institutes of Health guidelines for the care and use of animals in
research.
At 5 and 10 months of age, both WT and MCR4KO mice were
euthanized by CO2 inhalation and weighed to the nearest 0.1 g.
Lumbar vertebrae and femora were immediately harvested,
wrapped in sterile gauze soaked in PBS, and stored frozen at
220uC for subsequent biomechanical analyses. Prior to sacrifice,
in vivo whole body composition and BMD measurements were
carried out on anesthetized mice using dual-energy X-ray
absorptiometry (pixiMusH, GE Medical Systems, Waukesha, WI)
after an overnight fast. Analysis was performed using the mouse
whole body software provided by the manufacturer. BMD of
isolated femoral and L5 vertebral specimens were determined as
well.
Cortical femoral shaft bone geometry was assessed with a
desktop x-ray microtomographic scanner (SkyScan Model 1074,
Aartselaar, Belgium). Images were analyzed with Optimas
software (version 6.2; Media Cybernetics, Silver Spring, MD).
To determine femoral structural properties, the left femur was
tested to failure by three-point bending on a high-resolution
materials test apparatus (Model 4442, Instron Corp., Canton,
MA). Load and displacement data were recorded and failure load
was determined using system software. Vertebrae were evaluated
using a desktop mCT imaging system (mCT40; Scanco Medical
AG, Bassersdorf, Switzerland) equipped with a 10-mm focal spot
microfocus X-ray tube and images acquired with a 12 mm
isotropic voxel size, as previously described [28]. Morphometric
variables describing bone microstructure were computed using
direct 3D methods, including bone volume fraction (BV/TV, %),
trabecular number (Tb.N, mm
21), trabecular thickness (Tb.Th,
mm), trabecular separation (Tb.Sp, mm), connectivity density
(ConnD, mm
23), and the structure model index (SMI), a measure
of the plate- versus-rod-like nature of the trabecular structure. All
microCT analyses adhere to published guidelines [29].
Statistics
Data are expressed as mean 6 SEM. Statistical analysis was
performed using Prism software (Version 4.0, Prism Software
Corp., Irvine, CA). All data were analyzed with an unpaired t test,
or Pearson correlation. For all analyses, significance was assigned
at the level of P,0.05.
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